Dublin, July 26, 2024 (GLOBE NEWSWIRE) — The “Antibacterial Drugs – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.
The global market for Antibacterial Drugs is estimated at US$44.9 Billion in 2023 and is projected to reach US$58.6 Billion by 2030, growing at a CAGR of 3.9% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The growth in the antibacterial drugs market is driven by several factors, including technological advancements in drug discovery, the increasing prevalence of bacterial infections, and the rising awareness of antibiotic resistance. Technological advancements, such as high-throughput screening, genomics, and bioinformatics, have accelerated the discovery of new antibiotics and enhanced the understanding of bacterial resistance mechanisms.
These technologies enable researchers to identify novel drug targets and develop more effective antibacterial agents. The growing prevalence of bacterial infections, exacerbated by factors such as aging populations, increased hospitalizations, and the rising incidence of chronic diseases, continues to drive demand for effective antibacterial treatments.
Additionally, public health initiatives and educational campaigns have raised awareness about the dangers of antibiotic resistance, leading to increased demand for new and more effective antibacterial drugs. The development of rapid diagnostic tools to identify bacterial infections and resistance patterns is also propelling market growth, as these tools enable more targeted and effective treatments.
Furthermore, the support from government and non-government organizations in funding research and development activities, as well as regulatory incentives such as expedited review processes for new antibiotics, is fostering innovation in the market. Overall, the combination of these factors is driving sustained growth and innovation in the antibacterial drugs market, ensuring the continued effectiveness of these critical medicines in the fight against bacterial infections.
Key Questions Answered:
- How is the Global Antibacterial Drugs Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Key Insights:
- Market Growth: Understand the significant growth trajectory of the ?-lactams Drug Class segment, which is expected to reach US$35.4 Billion by 2030 with a CAGR of a 4.1%. The Macrolides Drug Class segment is also set to grow at 4.4% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $12.2 Billion in 2023, and China, forecasted to grow at an impressive 6.5% CAGR to reach $12.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Allergan PLC, AstraZeneca PLC, Bayer AG, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 244 |
| Forecast Period | 2023 – 2030 |
| Estimated Market Value (USD) in 2023 | $44.9 Billion |
| Forecasted Market Value (USD) by 2030 | $58.6 Billion |
| Compound Annual Growth Rate | 3.9% |
| Regions Covered | Global |
MARKET OVERVIEW
- Influencer Market Insights
- Global Economic Update
- Antibacterial Drugs – Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
MARKET TRENDS & DRIVERS
- Rising Incidence of Bacterial Infections Expands Addressable Market Opportunity for Antibacterial Drugs
- Advances in Drug Discovery Technologies Propel Growth in the Antibacterial Drugs Market
- Increasing Antibiotic Resistance Throws the Spotlight on New Drug Development
- Development of Novel Antibiotics Strengthens Business Case for Innovative Treatments
- High-Throughput Screening Techniques Accelerate Identification of New Antibacterial Compounds
- Genomic Research Spurs Growth by Uncovering New Drug Targets
- Integration of Bioinformatics in Drug Development Expands Market Potential
- Public Health Initiatives Drive Adoption of Responsible Antibiotic Use Programs
- Rising Awareness of Antibiotic Resistance Generates Demand for New Treatments
- Increasing Prevalence of Hospital-Acquired Infections Sustains Market Growth
- Expansion of Rapid Diagnostic Tools Enhances Market for Targeted Antibacterial Therapies
- Growth in Aging Population Expands Need for Effective Antibacterial Drugs
- Advances in Bacteriophage Therapy Generate Opportunities for Alternative Treatments
- Growing Use of Antimicrobial Peptides Propels Market Growth
- Evolving Healthcare Infrastructure in Emerging Markets Expands Market Reach for Antibacterial Drugs
FOCUS ON SELECT PLAYERS (Total 124 Featured)
- Allergan PLC
- AstraZeneca PLC
- Bayer AG
- Bristol-Myers Squibb Company
- GlaxoSmithKline PLC
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis International AG
- Pfizer, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/k3rire
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Global Antibacterial Drugs Market
